Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

With 44,000 new diagnoses each year, non-small cell lung cancer is the second most frequent neoplasm in Italy after breast ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

We must come together to combat air pollution and move to clean energy to prevent more needless deaths from lung cancer.

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...